08:25 AM EDT, 03/19/2025 (MT Newswires) -- Black Diamond Therapeutics ( BDTX ) and French pharmaceutical group Servier said Wednesday that they have signed a global licensing agreement in which Servier will develop and globally commercialize BDTX-4933, a targeted therapy for solid tumors.

Black Diamond will receive a $70 million upfront payment and will be eligible for up to $710 million in development and commercial sales milestone payments, as well as tiered royalties on international net sales, the parties said.

BDTX-4933 is currently in early-stage development to target RAS mutations and RAF alterations in solid tumors, the companies said.

Shares of Black Diamond were up 47% in recent Wednesday premarket activity.